Factor concentrates
We work closely with Haemophilia Treatment Centres to optimise patient care. Hospitals may request the following supplies from us:
Always read and refer to the product information sheets for further information on precautions, dosage and administration prior to giving factor concentrates.
|
|
|
Biostate® in 250 IU and 500 IU vials |
Biostate®
Biostate® is a lyophilised concentrate of human blood coagulation factor VIII and von Willebrand factor (vWF).
It is used to treat patients with von Willebrand Disease and occasionally Haemophilia A. It is available in the following presentations:
- 250 IU factor VIII / 500 IU vWF
- 500 IU factor VIII / 1,000 IU vWF
- 1,000 IU factor VIII / 2,000 IU vWF
Biostate® 1,000 IU factor VIII / 2,000 IU vWF supplied with 10 mL WFI 153 KB
Factor VIII is also available as a recombinant factor (Kogenate and Xyntha) and is now the preferred product for treatment and prophylaxis of Haemophilia A.
This does not contain von Willebrand Factor and is not indicated for the treatment of bleeding in von Willebrand disease.
Biostate® product information [on www.csl.com.au]
This link takes you to CSL's web information about Biostate®. You can download the product information (PI) sheet from this web page.
The PI details the pharmacology, indications, contraindications, precautions, adverse effects, use in pregnancy & lactation, adverse effects, and dosage & administration of Biostate®.
|
|
|
MonoFIX-VF 1000 IU vial |
MonoFIX-VF®
MonoFIX-VF® is a concentrate of coagulation factor IX and may be used for the treament and prophylaxis in some cases of patients with Haemophilia B.
It is available in 500 IU or 1000 IU vials.
Recombinant factor IX (Benefix) is available and is the preferred product for Haemophilia B.
MonoFIX-VF® is not indicated for the treatment of haemophilia A, patients with factor VIII inhibitors; or of factor II, VII or X deficiencies because it does not contain therapeutic levels of these coagulation factors.
MonoFIX-VF® product information [on www.csl.com.au]
This link takes you to CSL's web information about MonoFIX-VF. You can download the product information (PI) sheet from this web page.
The PI details the pharmacology, indications, contraindications, precautions, adverse effects, use in pregnancy & lactation, adverse effects, and dosage & administration of MonoFIX-VF.
|
|
|
Prothrombinex-VF 500 IU vial |
Prothrombinex-VF®
Prothrombinex-VF® is a coagulation factor concentrate containing factors II, IX and X and a small amount of factor VII.
It is used for prophylaxis and treatment of bleeding in patients with single or multiple congenital deficiencies of factor II or X, and in patients with single or multiple acquired prothrombin complex factor deficiency requiring partial or complete reversal (eg, reversal of warfarin anticoagulant therapy).
The dosage is 25–50 IU/kg for warfarin reversal.
Because of the potential risk of Prothrombinex-VF – induced thrombosis, Prothrombinex-VF should not be used for prophylaxis or treatment of haemorrhage in patients with haemophilia B if a highly-purified factor IX preparation, such as MonoFIX-VF, is available.
Prothrombinex-VF® product information [on www.csl.com.au]
This link takes you to CSL's web information about Prothrombinex-VF. You can download the product information (PI) sheet from this web page.
The PI details the pharmacology, indications, contraindications, precautions, adverse effects, use in pregnancy & lactation, adverse effects, and dosage & administration of Prothrombinex-VF.
Prothrombinex-VF FAQ (2009) 396 KB
Published by CSL Behring.
This document contains answers to frequently asked questions about Prothrombinex-VF, including indications, incidence of thrombotic adverse events, dosage for warfarin reversal, etc.
|
|
|
Thrombotrol-VF 1000 IU vial |
Thrombotrol-VF®
Thrombotrol-VF® is indicated in patients with inherited deficiency of antithrombin III (ATIII) for prophylaxis and treatment of thrombosis and pulmonary embolism during surgery, pregnancy and childbirth.
It may also be indicated in cases of acquired deficiencies such as liver disease and acute disseminated intravascular coagulation (DIC).
Thrombotrol-VF® product information [on www.csl.com.au]
This link takes you to CSL's web information about Thrombotrol-VF. You can download the product information (PI) sheet from this web page.
The PI details the pharmacology, indications, contraindications, precautions, adverse effects, use in pregnancy & lactation, adverse effects, and dosage & administration of Thrombotrol-VF.
192 KB
